CTI BioPharma Corp. is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CTIC’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that CTI BioPharma could be a solid choice for investors.
Current Quarter Estimates for CTIC
In the past 30 days, 1 estimate has gone higher for CTI BioPharma, with no downward revisions in the same time period. The trend has been pretty favorable too, with estimates narrowing down from a loss of 10 cents a share 30 days ago, to a loss of 9 cents a share today, a move of 11.1%.
Current Year Estimates for CTIC
Meanwhile, CTI BioPharma’s current year figures are also looking quite promising, with 2 estimates moving higher in the past month, with no downward revisions. The consensus estimate trend has also seen a boost for this time frame, narrowing down from a loss of 32 cents per share 30 days ago to a loss of 25 cents per share today, an increase of 28%.
Bottom Line
The stock has also started to move higher lately, adding 7.1% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
CTI BioPharma Corp. is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CTIC’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that CTI BioPharma could be a solid choice for investors.
Current Quarter Estimates for CTIC
In the past 30 days, 1 estimate has gone higher for CTI BioPharma, with no downward revisions in the same time period. The trend has been pretty favorable too, with estimates narrowing down from a loss of 10 cents a share 30 days ago, to a loss of 9 cents a share today, a move of 11.1%.
Current Year Estimates for CTIC
Meanwhile, CTI BioPharma’s current year figures are also looking quite promising, with 2 estimates moving higher in the past month, with no downward revisions. The consensus estimate trend has also seen a boost for this time frame, narrowing down from a loss of 32 cents per share 30 days ago to a loss of 25 cents per share today, an increase of 28%.
Bottom Line
The stock has also started to move higher lately, adding 7.1% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>